Pfizer's $819 Million Trading Day Ranks 85th as Stock Climbs 2.37% in Two Days

On April 25, 2025, Pfizer's trading volume reached $819 million, ranking 85th in the day's market activity. The stock rose by 0.61%, marking its second consecutive day of gains, with a total increase of 2.37% over the past two days.

Pfizer has entered into a strategic collaboration with Guardant Health to advance the development and commercialization of new cancer therapies. This multi-year partnership will integrate Guardant's liquid biopsy tests into Pfizer's global clinical studies, enabling the assessment of circulating tumor DNA as a surrogate endpoint for therapy response monitoring. The agreement also includes access to Guardant's liquid biopsy tests in China for Pfizer's global clinical trials, which involve Chinese cohorts.

Pfizer's commitment to shareholder returns was highlighted by the declaration of its second-quarter 2025 dividend. The company's board of directors approved a quarterly cash dividend of $0.43 per share, payable on June 13, 2025, to shareholders of record as of May 9, 2025. This marks Pfizer's 346th consecutive quarterly dividend payment, underscoring the company's long-standing dedication to returning value to its shareholders.

At the ASCO 2025 Annual Meeting, Pfizer presented significant oncology research, featuring over 60 abstracts, including 15 oral presentations. Key highlights included the primary analysis of the BREAKWATER study investigating BRAFTOVI combination therapy in colorectal cancer and the VERITAC-2 study results for vepdegestrant in breast cancer. The presentations supported Pfizer's goal of delivering eight breakthrough cancer medicines by 2030, with nine new pivotal Phase 3 trials planned for 2025.

The CDC's Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for Pfizer’s RSV vaccine ABRYSVO® to include adults aged 50 to 59 at increased risk of RSV-associated lower respiratory tract disease. This expansion specifically includes ABRYSVO®, which received FDA approval in October 2024 for preventing RSV-associated LRTD in at-risk adults aged 18-59. The vaccine now offers the broadest RSV indication in the EU, covering both active immunization for adults 18 and older, and passive protection for infants through maternal immunization during pregnancy.

Pfizer announced the discontinuation of danuglipron, its oral GLP-1 receptor agonist being developed for chronic weight management. The decision came after a participant experienced potential drug-induced liver injury, which resolved after discontinuing the treatment. Despite this setback, Pfizer remains committed to advancing treatments for cardiovascular and metabolic diseases, including obesity, through their oral GIPR antagonist candidate and other early-stage obesity programs.